|
1.
|
Ellison LF and Wilkins K: An update on
cancer survival. Health Rep. 21:55–60. 2010.
|
|
2.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3.
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
4.
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
5.
|
Conroy T, Paillot B, François E, et al:
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil
in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the
Federation Nationale des Centres de Lutte Contre le Cancer study. J
Clin Oncol. 23:1228–1236. 2005. View Article : Google Scholar
|
|
6.
|
Ducreux M, Boige V and Malka D: Treatment
of advanced pancreatic cancer. Semin Oncol. 34:S25–S30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
8.
|
Wang Z, Li Y, Ahmad A, et al: Pancreatic
cancer: understanding and overcoming chemoresistance. Nat Rev
Gastroenterol Hepatol. 8:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
et al: Cancer stem cell markers in common cancers - therapeutic
implications. Trends Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Liu QH, Zhang J, Zhao CY, et al: Surviving
cells after treatment with gemcitabine or 5-fluorouracil for the
study of de novo resistance of pancreatic cancer. Cancer Lett.
314:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Bonner-Weir S and Sharma A: Pancreatic
stem cells. J Pathol. 197:519–526. 2002. View Article : Google Scholar
|
|
12.
|
O’Brien CA, Kreso A and Jamieson CH:
Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120.
2010.
|
|
13.
|
Zhang YQ, Kritzik M and Sarvetnick N:
Identification and expansion of pancreatic stem/progenitor cells. J
Cell Mol Med. 9:331–344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lee CJ, Dosch J and Simeone DM: Pancreatic
cancer stem cells. J Clin Oncol. 26:2806–2812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Quante M and Wang TC: Stem cells in
gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol.
6:724–737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wang JC and Dick JE: Cancer stem cells:
lessons from leukemia. Trends Cell Biol. 15:494–501. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Zou GM: Cancer initiating cells or cancer
stem cells in the gastrointestinal tract and liver. J Cell Physiol.
217:598–604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Haraguchi N, Utsunomiya T, Inoue H, et al:
Characterization of a side population of cancer cells from human
gastrointestinal system. Stem Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Haraguchi N, Inoue H, Tanaka F, et al:
Cancer stem cells in human gastrointestinal cancers. Hum Cell.
19:24–29. 2006. View Article : Google Scholar
|
|
20.
|
Hermann PC, Bhaskar S, Cioffi M and
Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol.
20:77–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zhou J, Wang CY, Liu T, et al: Persistence
of side population cells with high drug efflux capacity in
pancreatic cancer. World J Gastroenterol. 14:925–930. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar
|
|
23.
|
Arumugam T, Ramachandran V, Fournier KF,
et al: Epithelial to mesenchymal transition contributes to drug
resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kim MP and Gallick GE: Gemcitabine
resistance in pancreatic cancer: picking the key players. Clin
Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Rückert F, Werner K, Aust D, et al:
Immunohistological analysis of six new primary pancreatic
adenocarcinoma cell lines. Global J Biochem. 3:112012.
|
|
27.
|
Rückert F, Aust D, Böhme I, et al: Five
primary human pancreatic adenocarcinoma cell lines established by
the outgrowth method. J Surg Res. 172:29–39. 2012.PubMed/NCBI
|
|
28.
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ke N, Wang X, Xu X and Abassi YA: The
xCELLigence system for real-time and label-free monitoring of cell
viability. Methods Mol Biol. 740:33–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sipos B, Moser S, Kalthoff H, et al: A
comprehensive characterization of pancreatic ductal carcinoma cell
lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444–52. 2003.PubMed/NCBI
|
|
32.
|
Neureiter D, Zopf S, Dimmler A, et al:
Different capabilities of morphological pattern formation and its
association with the expression of differentiation markers in a
xenograft model of human pancreatic cancer cell lines.
Pancreatology. 5:387–397. 2005. View Article : Google Scholar
|
|
33.
|
Hong SP, Wen J, Bang S, Park S and Song
SY: CD44-positive cells are responsible for gemcitabine resistance
in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Du Z, Qin R, Wei C, et al: Pancreatic
cancer cells resistant to chemoradiotherapy rich in
‘stem-cell-like’ tumor cells. Dig Dis Sci. 56:741–750.
2011.PubMed/NCBI
|
|
35.
|
Quint K, Stintzing S, Alinger B, et al:
The expression pattern of PDX-1, SHH, Patched and Gli-1 is
associated with pathological and clinical features in human
pancreatic cancer. Pancreatology. 9:116–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Wen J, Park JY, Park KH, et al: Oct4 and
Nanog expression is associated with early stages of pancreatic
carcinogenesis. Pancreas. 39:622–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Fan CM and Tessier-Lavigne M: Patterning
of mammalian somites by surface ectoderm and notochord: evidence
for sclerotome induction by a hedgehog homolog. Cell. 79:1175–1186.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Li X, Deng W, Lobo-Ruppert S and Ruppert
J: Gli1 acts through Snail and E-cadherin to promote nuclear
signaling by β-catenin. Oncogene. 26:4489–4498. 2007.PubMed/NCBI
|
|
39.
|
Hotz B, Arndt M, Dullat S, et al:
Epithelial to mesenchymal transition: expression of the regulators
Snail, Slug, and Twist in pancreatic cancer. Clin Cancer Res.
13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Missol-Kolka E, Karbanová J, Janich P, et
al: Prominin-1 (CD133) is not restricted to stem cells located in
the basal compartment of murine and human prostate. Prostate.
71:254–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Karbanová J, Missol-Kolka E, Fonseca AV,
et al: The stem cell marker CD133 (Prominin-1) is expressed in
various human glandular epithelia. J Histochem Cytochem.
56:977–993. 2008.PubMed/NCBI
|
|
42.
|
Immervoll H, Hoem D, Sakariassen PØ,
Steffensen OJ and Molven A: Expression of the ‘stem cell marker’
CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC
Cancer. 8:482008.
|
|
43.
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
